Brand
Amgen
AI Visibility Intelligence
Where Amgen Is Winning and Losing AI Buyer Visibility
Live AI Knowledge Base
We've already fixed where Amgen is losing visibility.
Based on this analysis, we created pages that help Amgen show up when buyers search for these questions. These pages are already live at amgen-com.aikb.tryreadable.ai.
These pages directly address missing visibility
“bulk biologic drug manufacturing partner for healthcare enterprises”Not mentioned beforeNow covered“Gilead Sciences hepatitis C portfolio vs Vertex Pharmaceuticals rare disease focus”Not mentioned beforeNow covered“Gilead Sciences vs Vertex Pharmaceuticals drug development pipeline comparison”Not mentioned beforeNow covered“global pharmaceutical manufacturer specializing in biotechnology-derived medicines”Not mentioned beforeNow covered
AI influence score for AmgenThis score estimates how often AI answers mention and recommend your brand across buyer and comparison prompts. Higher scores mean stronger visibility.
45
out of 100
Losing ~52% of buyers using AI search
Companies with higher scores are more likely to appear in AI-driven purchases.
Where AI is choosing Amgen vs competitors
Losing ~52% of buyers using AI search
Amgen is missing in 58% of tracked prompts right now. Every missed answer is a likely lost sale.
Where AI already picks you
- AI already links Amgen with Clinical Trial Experience. Regeneron Pharmaceuticals does not outrank Amgen here.
Where competitors beat you
- Competitors beat Amgen on Gmp Certifications. Regeneron Pharmaceuticals is rated strong while Amgen is limited.
- Competitors beat Amgen on Quality Systems. Gilead Sciences is rated moderate while Amgen is limited.
- Competitors beat Amgen on Scale-up Capabilities. Regeneron Pharmaceuticals is rated moderate while Amgen is limited.
What to fix first
Close the Gmp Certifications gap before competitors keep owning the recommendation.
Buyers are asking about Gmp Certifications, but your homepage barely explains it. Regeneron Pharmaceuticals currently has the stronger AI association.
Regeneron Pharmaceuticals is strong here while Amgen is limited. Homepage copy barely mentions Gmp Certifications.
Need help fixing this?
Book a report review with our team
We'll show where AI is missing Amgen, which buyer queries matter most, and what to publish first to improve visibility.
How AI compares Amgen across buyer and comparison queries
Amgen appears in 33% of buyer queries and 100% of direct comparison queries that explicitly mention Amgen. Regeneron Pharmaceuticals appears in 33% of buyer queries.
Confidence: MediumSignal confidence is medium. Trends are useful but should be validated with deeper sampling.
Comparison Mentions counts only direct comparison prompts that explicitly include Amgen. Total Mentions counts all sampled buyer and comparison prompts.
These rows show the competitor brands AI actually surfaces in the sampled buyer queries, plus how those same brands carry into direct comparisons and overall visibility.
| Brand | Buyer Query Visibility | Comparison Query Visibility | Overall Visibility |
|---|---|---|---|
| Amgen Your brand | 33% | 100% | 42% |
| Regeneron Pharmaceuticals | 33% | 100% | 42% |
| Vertex Pharmaceuticals | 17% | 0% | 33% |
Where competitors still intercept demand
Same underlying gaps, reframed around where competitors still capture buyer demand before Amgen gets recommended.
Buyer
global pharmaceutical manufacturer specializing in biotechnology-derived medicines
Competitor leading: Regeneron Pharmaceuticals
Create a buyer-intent page aligned to this query so Amgen appears in discovery results.
Where AI thinks you win vs lose
Directional view based on current AI response patterns, not a full product benchmark.
| Attribute | Amgen | Regeneron Pharmaceuticals | Gilead Sciences | Vertex Pharmaceuticals |
|---|---|---|---|---|
| Gmp Certifications | ||||
| Clinical Trial Experience | ||||
| Regulatory Approvals | ||||
| Manufacturing Capacity | ||||
| Quality Systems | ||||
| Scale-up Capabilities |
Where Amgen Is Losing AI Buyers to Competitors
Immediate risk
Amgen is absent in 67% of buyer-intent queries while Regeneron Pharmaceuticals appears in 42% of tracked prompts.
Prompts you're missingThe share of analyzed prompts where Amgen was not mentioned at all. Higher numbers mean more missed AI visibility.
58%
Buyer query lossesThe share of buyer-intent prompts where Amgen did not appear in the AI answer. Higher numbers mean more likely lost demand.
67%
Comparison coverageThe share of direct comparison prompts that explicitly include Amgen where Amgen was mentioned. Higher numbers mean stronger visibility when buyers compare options.
100%
Top competitor by mentionsThe competitor that appeared most often across all analyzed prompts, based on AI mentions in this report sample.
Regeneron Pharmaceuticals (42%)
What buyers hear first
Amgen and Regeneron achieve equal visibility (42%) in AI responses, but Amgen dominates manufacturing-focused comparisons while Regeneron appears in broader biotech category positioning alongside Genentech and Biogen
Sample-basedComparison signalCoverage signal
What buyers hear first
AI assistants position Amgen as a scale and reliability leader with decades of operational maturity, while Regeneron is framed as an innovation-focused competitor with next-generation manufacturing technologies
Sample-basedCompetitive signal
What you lose if this continues
Gilead (25%) and Vertex (33%) are underrepresented in manufacturing queries but dominate therapeutic-area comparisons, indicating AI assistants segment these brands by product portfolio rather than manufacturing capability
Sample-basedComparison signalCoverage signal
Act now
Create dedicated comparison pages positioning Amgen against Vertex and Gilead on therapeutic breadth and manufacturing scale; ensure these pages cite Amgen's oncology, immunology, and rare disease portfolios to capture disease-specific AI recommendations
Every missed buyer-intent prompt is a competitor recommendation opportunity.
Detailed interpretation
- Amgen and Regeneron achieve equal visibility (42%) in AI responses, but Amgen dominates manufacturing-focused comparisons while Regeneron appears in broader biotech category positioning alongside Genentech and Biogen
- AI assistants position Amgen as a scale and reliability leader with decades of operational maturity, while Regeneron is framed as an innovation-focused competitor with next-generation manufacturing technologies
- Gilead (25%) and Vertex (33%) are underrepresented in manufacturing queries but dominate therapeutic-area comparisons, indicating AI assistants segment these brands by product portfolio rather than manufacturing capability
Amgen visibility gaps in AI search results
- Regeneron appears in 5 of 6 comparison queries while Amgen appears in only 3; Amgen is absent from pipeline, rare disease, and antiviral comparisons where competitors establish therapeutic credibility
- Vertex and Gilead capture therapeutic-area authority in AI responses (cystic fibrosis, hepatitis C, rare diseases) while Amgen lacks positioning in disease-specific or indication-focused comparison pages
- Hospital supply chain and injectable biologics queries mention Roche, Novartis, Eli Lilly, and Pfizer—not Amgen—suggesting Amgen is missing from distribution and hospital formulary positioning narratives
Where AI mentions Amgen in buyer and comparison queries
Recommended AI search optimizations for Amgen
- Create dedicated comparison pages positioning Amgen against Vertex and Gilead on therapeutic breadth and manufacturing scale; ensure these pages cite Amgen's oncology, immunology, and rare disease portfolios to capture disease-specific AI recommendations
- Develop content establishing Amgen's supply chain reliability and hospital distribution network as primary differentiators; target citations in hospital formulary, cold-chain logistics, and global distribution authority sources to compete with Roche and Novartis positioning
- Build category authority pages linking Amgen's manufacturing capabilities to specific therapeutic modalities (monoclonal antibodies, recombinant proteins, biosimilars); ensure technical documentation and regulatory approval data are indexed and cited by AI systems to address the 0% association with GMP certifications and regulatory attributes
Everyday you may be losing hundreds of buyers using AI search. You should act now and stop losing customers to your competitors. Schedule a free call with us to learn how to win in AI search.
Where To Explore Next
Parent industry
Manufacturing
Use the industry hub to understand category leaders, visibility benchmarks, and the broader market context.
Manufacturing industry intelligenceRelated analyses
Buyer queries shaping this report
- Open bulk biologic drug manufacturing partner for healthcare enterprises analysis
- Open Gilead Sciences hepatitis C portfolio vs Vertex Pharmaceuticals rare disease focus analysis
- Open Gilead Sciences vs Vertex Pharmaceuticals drug development pipeline comparison analysis
- Open global pharmaceutical manufacturer specializing in biotechnology-derived medicines analysis
Related brands
Other brands with live reports in this category
Need help fixing this?
Book a report review with our team
We'll show where AI is missing Amgen, which buyer queries matter most, and what to publish first to improve visibility.